Parvalbumin: calcium and magnesium buffering in the distal nephron by Olinger, Eric et al.
Parvalbumin: calcium and magnesium buffering in the distal
nephron
Eric Olinger, Beat Schwaller, Johannes Lofﬁng, Philippe Gailly and Olivier Devuyst
Division of Nephrology and Laboratory of Cell Physiology, UCL Medical School, Brussels, Belgium, Institutes of Physiology and
Anatomy, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland and Unit of Anatomy,
Department of Medicine, University of Fribourg, Fribourg, Switzerland
Correspondence and offprint requests to: Olivier Devuyst; E-mail: olivier.devuyst@uzh.ch
Abstract
Parvalbumin (PV) is a classical member of the EF-hand
protein superfamily that has been described as a Ca2+
buffer and Ca2+ transporter/shuttle protein and may also
play an additional role in Mg2+ handling. PV is exclu-
sively expressed in the early part of the distal convoluted
tubule in the human and mouse kidneys. Recent studies in
Pvalb knockout mice revealed a role of PV in the distal
handling of electrolytes: the lack of PV was associated
with a mild salt-losing phenotype with secondary aldos-
teronism, salt craving and stronger bones compared with
controls. A link between the Ca2+-buffering capacity of
PV and the expression of the thiazide-sensitive Na+–Cl−
cotransporter was established, which could be relevant to
the regulation of sodium transport in the distal nephron.
Variants in the PVALB gene that encodes PV have been
described, but their relevance to kidney function has not
been established. PV is also considered a reliable marker
of chromophobe carcinoma and oncocytoma, two neo-
plasms deriving from the distal nephron. The putative role
of PV in tumour genesis remains to be investigated.
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Properties and distribution of parvalbumin
Parvalbumin (PV) is a small protein (109 amino acids in
most species; molecular mass ∼12 kDa) ﬁrst isolated
from carp muscle in 1973 [1] and belonging to the sub-
family of cytosolic Ca2+ buffers in the superfamily of EF-
hand proteins [2]. Proteins of the EF-hand family are
characterized by a conserved, helix–loop–helix structural
unit, which consists of two α-helices bridged by a Ca2+-
chelation loop. These proteins are involved in the regulation
of many critical cellular processes including gene
transcription, protein phosphorylation, nucleotide metab-
olism and ion transport [3–5]. Over 200 members of the
Ca2+-binding EF-hand superfamily have been identiﬁed
so far in the human genome [2].
PV is characterized by a high afﬁnity for Ca2+ (dis-
sociation constant KD,Ca: ∼5–10 nM) and an intermediate
afﬁnity for Mg2+ (KD,Mg: ∼30 μM). Thus, the two func-
tional metal-binding sites are so-called mixed (Ca2+/Mg2+)-
binding sites. These properties and the fact that the intra-
cellular concentration of Mg2+ [(Mg2+)cyt, 0.5–1 mM]
exceeds largely that of Ca2+ [(Ca2+)cyt, 50–100 nM] in
basal conditions explain why PV-binding sites are (>80%)
occupied mainly by Mg2+ in a resting cell. The remaining
sites are either Ca2+-bound or metal-free. When a stimulus
induces a rise in [Ca2+]cyt levels, Mg
2+ slowly dissociates
from the binding sites and is replaced by Ca2+. Because of
the slow Ca2+-binding kinetics under physiological con-
ditions, which mainly results from this prior Mg2+ dis-
sociation, PV is referred to as a slow-onset Ca2+ buffer [2].
Binding of two Ca2+ ions to the Ca2+-binding sites induces
a rather insigniﬁcant conformational change [4]. Hence,
PV is mostly considered a pure Ca2+ buffer, with little or
no Ca2+ sensing and direct regulatory properties [6].
The expression of PV is remarkably restricted to a few
cell types in the brain, skeletal and heart muscles, para-
thyroid glands and kidney [7–9]. In the central nervous
system, PV is highly expressed in inhibitory GABAergic
interneurons, e.g. in the cortex in chandelier (axo-axonic)
and basket cells. These cortical neurons play an important
role in controlling pyramidal cell excitability. The absence
of PV in these cells is linked to increased drug-induced
seizure susceptibility [10]. PV is also expressed in similar
types of interneurons in the hippocampus (axo-axonic and
basket cells) and cerebellum (stellate and basket cells) [7].
In the cerebellum, PV is additionally expressed in Pur-
kinje cells.
In the kidney, PV is expressed in the epithelial cells
lining a subset of tubules in the distal nephron (Figure 1).
In the mouse and human kidneys, PV appears to be exclu-
sively expressed in the early part of the distal convoluted
tubule (early DCT, or DCT1), where it colocalizes with the
thiazide-sensitive apical Na+–Cl− cotransporter (NCC).
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The progression between the early and late part of the DCT
is characterized by an abrupt transition from PV (early
DCT) to calbindin-D28k (late DCT, or DCT2). Cells ex-
pressing calbindin-D28k also express NCC and epithelial
Na+ channel (ENaC) [11, 12]. In the rat kidney, PV has
been located in the thick ascending limb (TAL) of the
loop of Henle, late DCT, connecting tubule (CNT) and
intercalated cells of the collecting duct [13]. Immuno-
cytochemical analyses revealed that in most tubular
cells, PV shows a diffuse cytosolic pattern, with a signal
sometimes enhanced along the basolateral membrane
[12, 13].
PV is present in fast-contracting and fast-relaxing skel-
etal muscle ﬁbres (e.g. extensor digitorum longus or tibia-
lis anterior) [14]. The protein has also been detected in
normal and in hyperplastic and adenomatous human para-
thyroid glands, with the strongest expression in chief cells
and water clear cells. Of note, PV colocalizes with the
parathyroid hormone (PTH) in the same cell types [8].
Role of PV in the distal nephron
The distal nephron plays a major role in the reabsorption
of NaCl and the regulation of the ﬁnal excretion of Ca2+
and Mg2+, under the inﬂuence of several hormones, in-
cluding aldosterone, PTH and 1,25(OH)2-vitamin D3
[15]. Approximately 5% of the ﬁltered load of NaCl is
reabsorbed in the DCT, involving the thiazide-sensitive
NCC on the apical side and the Na+-K+-ATPase and the
ClC-Kb chloride channel on the basolateral side of the
cells. The reabsorption of Ca2+ and Mg2+ in that segment
is mediated by a complex interaction of different proteins,
involving two speciﬁc members of the transient receptor
potential (TRP) channel superfamily that have a distinct
spatial distribution along the DCT (Figure 2). Approxi-
mately 5–10% of ﬁltered Mg2+ is passively reabsorbed
through the apical TRPM6 channel and basolateral active
transport systems in the DCT1. Speciﬁc intracellular
Fig. 1. Structure and distribution of PV in the kidney. (A) Segmentation of the distal nephron, with distribution of speciﬁc markers in the early
(DCT1) and late (DCT2) parts of the distal convoluted tubule, the CNT and the cortical collecting duct (CCD). PV is exclusively expressed in the
DCT1, where it colocalizes with the apical NCC. It is of note that the mediators of Ca2+ reabsorption are expressed in more distal nephron segments
(TRPV5; NCX, sodium-calcium exchanger; PMCA, plasma membrane calcium ATPase; CB, calbindin-D28K). The epithelial Na
+ channel ENac and
CB are expressed all along distal nephron segments, starting in DCT2. MR, medullary ray; G, glomerulus. Modiﬁed from Lofﬁng et al. [11]. (B)
Immunostaining for PV in the human kidney cortex reveals a diffuse cytosolic localization (green signal), sometimes clustered above the basolateral
membrane, in cells that express NCC in the apical membrane (red signal). (C) Solution structure of Ca2+-bound human PV. The CD domain (green)
and EF domain (yellow/red) bind one Ca2+ ion each (green spheres) in canonical Ca2+-binding loops of 12 amino acids. The helices E and F that
gave the name to all EF-hand proteins are marked by letters. Both Ca2+-binding loops in PV are of the Ca2+/Mg2+mixed type. The amino- (N) and
carboxy- (C) termini are labelled. The image was generated with PDB ProteinWorkshop 1.50 and is modiﬁed from Schwaller et al. [2].
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Mg2+ carriers and basolateral extrusion proteins have not
yet been identiﬁed. Apical TRPV5 channels (previously
named epithelial calcium channel 1, ECaC1) mediate the
passive entry of Ca2+ in the DCT2, before active, basolat-
eral transport via the Na+–Ca2+ exchanger 1 (NCX1) and
plasma membrane Ca2+-ATPase 1b (PMCA 1b). In the
DCT, TRPV5 colocalizes with the intracellular Ca2+
buffer/sensor calbindin-D28K [16, 17]. Studies in rabbit
CNTs have shown that calbindin-D28K could be important
to lower [Ca2+]cyt levels in order to maintain the necessary
gradient for passive cellular Ca2+ entry and to facilitate
the intracellular Ca2+ diffusional ﬂux [18]. Of interest, the
Ca2+ buffer calbindin-D9k is also expressed in DCT2, but
with a more focused expression than CB-D28k that
extends further into the CNTs and collecting ducts
(J. Lofﬁng, personal communication).
In view of the speciﬁc expression of PV in DCT1,
Belge et al. [12] investigated in detail the renal phenotype
of knockout mice (KO) for PV. In comparison with wild-
type littermates, Pvalb KO mice had increased diuresis
and kaliuresis at baseline, with secondary aldosteronism
and salt craving. As expected, an acute administration of
the loop diuretic furosemide, aimed to increase sodium
delivery in the DCT, led to increased diuresis and natriur-
esis/kaliuresis in both genotypes. However, surprisingly,
this treatment did not increase calciuria in Pvalb KO
mice. Furthermore, Pvalb KO mice showed no signiﬁcant
diuretic response to hydrochlorothiazide, but rather an ac-
centuated hypocalciuria. The PV-deﬁcient mice also
showed an increased bone mineral density. These func-
tional changes were explained by a strongly decreased
expression of NCC at the mRNA and protein levels in the
early DCT of Pvalb KO kidneys, in the absence of any
ultrastructural changes [12]. The Pvalb KO mice mani-
fested a decreased lithium clearance, suggesting that a
compensatory increase in sodium transport was taking
place in the proximal tubule—as it has been reported in
the case of long-term treatment with thiazide diuretics tar-
geting NCC [19].
What could be the link between the Ca2+/Mg2+-buffer-
ing capacities of PV and the expression of NCC in the
DCT cells? It has been known for a long time that the
entire distal nephron, and DCT cells in particular, ex-
presses luminal P2Y2 receptors, which trigger rapid intra-
cellular Ca2+ transients when stimulated by purinergic
agonists such as adenosine triphosphate (ATP) and
Fig. 2. Transcellular transport of Ca2+ and Mg2+ in the distal nephron. The segmentation of the DCT is reﬂected by a selective transport machinery
facilitating the reabsorption of Mg2+ in the proximal part of the DCT (DCT1), whereas the Ca2+ transport is restricted to the more distal part of the
DCT (DCT2) and the CNT (not represented on the ﬁgure). Magnesium enters the cells lining the DCT1 through apical TRPM6 channels. The nature
of the possible transporter and basolateral extruder protein remains unknown. PV is selectively expressed in the cytosol of these cells and plays a role
in regulating the Ca2+ signalling and the expression of the sodium-chloride cotransporter NCC. The transcellular transport of Ca2+ is mediated
through apical TRPV5 channels in the DCT2 and in the CNT. The Ca2+ buffer calbindin-D28K is carrying Ca
2+ ions to the basolateral membrane,
where they are extruded by the plasma membrane Ca2+ ATPase (PMCA1b) and NCX1.
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uridine triphosphate (UTP) [20]. These brief [Ca2+]cyt
transients cause a decrease in several transport systems in-
cluding those involved in NaCl reabsorption [21]. Studies
in a mouse DCT (mDCT) cell line showed that PV modu-
lates the shape and duration of intracellular Ca2+ transients
induced by ATP [12]. In turn, these changes were re-
ﬂected by major modiﬁcations in the expression of
endogenous NCC expression in these cells. The fact that
PV is capable of effectively reducing the amplitude of
ATP-evoked elevations in [Ca]cyt in mDCT cells [12]
could be potentially linked to the regulation of NCC
expression. Taken together, these studies conducted in
Pvalb KO mice and in mDCT cells suggest that PV could
regulate the expression of NCC by modulating intracellu-
lar Ca2+ signalling in response to extracellular ATP in
DCT cells.
Potential roles of PV in Ca2+ and Mg2+ handling
by the kidney
Considering the buffering properties of PV, one may
hypothesize that this protein could play a direct role in the
transepithelial handling of Ca2+ and Mg2+ in the distal
nephron. The major sites for transcellular Ca2+ reabsorp-
tion in mouse kidney are the late DCT and the CNT [11].
The early part of the DCT appears to play a minor role in
Ca2+ transport as apical TRPV5 and basolateral NCX and
PMCA are either not detected or only weakly expressed
in this segment (Figures 1 and 2). The exclusive distri-
bution of PV in the early DCT and the fact that its
expression is independent of the vitamin D3 status also
argues against a major role in distal calcium handling [13,
18]. Nevertheless, Pvalb KO mice show an increased
bone mineral density and a strongly positive calcium
balance when stimulated by thiazide diuretics [12]. In
fact, such a phenotype is consistent with a reduced NCC
expression in the DCT, similar to chronic thiazide admin-
istration. Volume contraction in the Pvalb KO mice is
probably an important factor to explain the positive
calcium balance, as indicated by decreased lithium clear-
ance [12, 19]. Nonetheless, other components of the
Ca2+-signalling toolkit [3] might be modiﬁed in Pvalb
KO mice and a study to address this question is underway
(Schwaller, unpublished work).
It must be pointed out that even volume-repleted Pvalb
KO mice tend to excrete less calcium than their wild-type
littermates [12], which could in fact originate from a dys-
functional NCC. Gesek and Friedman [22] demonstrated
that a reduced Cl− entry in DCT cells leads to decreased
intracellular Cl− activity followed by hyperpolarization of
the plasma membrane. The hyperpolarization was pro-
posed to activate dihydropyridine-sensitive calcium chan-
nels in the apical membrane, which enhances transcellular
Ca2+ transport [22]. A similar mechanism could operate
in DCT cells lacking PV, due to the down-regulation of
NCC. However, it is unclear whether a hyperpolarization
of the luminal membrane would persist under the chronic
conditions of a life-long decrease in NCC activity. Alter-
natively, a decreased urinary calcium excretion may also
be explained by a decreased intracellular Na+ concen-
tration, resulting from a decreased apical NCC activity. In
this scenario, basolateral NCX1 responds by facilitating
Na+ entry into the cell and Ca2+ exit out of the cell, en-
hancing the net transcellular Ca2+ ﬂux [23]. A third mech-
anism could be related to a structural hypertrophy of the
TRPV5 and NCX/PMCA1b-positive CNT, as observed in
NCC-deﬁcient mice [24], which would increase the epi-
thelial surface available for transcellular Ca2+ reabsorp-
tion. Nevertheless, careful histological examinations have
not detected such damages in the kidneys of the Pvalb
KO mice. Similarly, no compensatory up-regulation of
TRPV5 or calbindin-D28k, as observed after chronic
administrations of thiazide diuretics [25], has been ob-
served in the Pvalb KO kidneys.
Elegant studies have shown that calbindin-D28k, which
is expressed in DCT2, may make use its Ca2+-sensing
properties to function differently at basal [Ca2+]cyt and at
elevated levels caused by a Ca2+ inﬂux. Accordingly,
elevated [Ca2+]cyt levels could induce conformational
changes and regulatory processes including a negative
feedback on the apical TRPV5 [17]. Nevertheless, such a
mechanism seems unlikely to occur for PV, which is more
a ‘simple’ Ca2+ buffer protein than a Ca2+ sensing and
regulatory protein.
PV is distributed, along with TRPM6 and NCC, in the
DCT1 segment that plays a crucial role in Mg2+ handling.
The afﬁnity of PV for Mg2+ (KMg: ∼30 μM) makes a suit-
able candidate to feasibly act as an intracellular Mg2+
transporter/shuttle. For instance, inappropriate urinary loss
of Mg2+ is a hallmark of Gitelman syndrome (GS), an in-
herited tubulopathy due to loss-of-function mutations in
NCC (see below). Intracellular Mg2+ (and also Ca2+) con-
centrations tightly regulate their own reuptake through a
negative feedback involving apical transporters (TRPM6,
TRPV5). Changes in [Mg2+]cyt have been shown to
modify regulatory elements in non-coding mRNA
regions, also inﬂuencing the transcription of Mg2+ trans-
porters in bacteria [26]. Accordingly, a loss of PV could
induce such a negative feedback (decreased apical
TRPM6), which would decrease the gradient for passive
cellular Mg2+ entry and impair Mg2+ diffusional ﬂux [17,
27]. A mild Mg2+ wasting phenotype has been observed
in Pvalb KO mice on a C57BL/6J background (Olinger,
unpublished work), but further investigations have to be
done to conﬁrm these ﬁndings.
It is important to mention that there are signiﬁcant
differences between Slc12a3 KO mice lacking NCC and
those lacking PV. Most importantly, NCC-null mice show
a more substantial and constant Mg2+ loss in urine and
hypomagnesaemia at baseline, probably consistent with
severe DCT damage/loss and a loss of TRPM6-expressing
cells in the distal nephron. The morphological alterations
in DCT seem to be limited to its early part and are most
likely a result from reduced transcellular Na+ transport,
raising the question why these ultrastructural changes
were not observed in the Pvalb KO mice [12, 24].
Perhaps, the reduction in NCC activity and hence trans-
cellular Na+ transport in the DCTs of PV-deﬁcient mice is
not severe enough to provoke the structural changes as
they occur in mice lacking any NCC activity. Experiments
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addressing this issue are underway in the laboratory of
Lofﬁng.
PVALB as candidate gene in Gitelman syndrome
The combination of mild sodium wasting, resistance to
thiazide diuretics, hypocalciuria and increased bone
density observed in Pvalb KO mice is reminiscent of the
manifestations of GS. GS is a recessively inherited salt-
losing tubulopathy with hypokalemic alkalosis, hypomag-
nesaemia and hypocalciuria. The majority of patients with
GS are compound heterozygous for loss-of-function
mutations in the SLC12A3 gene that codes for the NCC
[28]. A few cases are caused by mutations in the
CLCNKB gene that codes for the basolateral ClC-Kb
chloride channel in DCT cells [28, 29]. GS is probably
the most common tubulopathy, with a prevalence of het-
erozygous carrier of an SLC12A3 mutation estimated at
1% in European populations [30]. Most patients with GS
are diagnosed in adulthood and are typically normoten-
sive, with a mild phenotype. Recent studies have pointed
to the possibility of severe complications, sometimes in-
volving children and potentially related to male gender
and speciﬁc allele combinations [31].
Despite advances in mutation detection in SLC12A3,
up to 30% of patients with GS carry only a single mutant
allele and negative SLC12A3 screening is observed in
∼10% of patients [29, 31]. Mutations in another gene
could thus explain the lack of detection of mutant
SLC12A3 alleles in GS patients. Considering the pheno-
type of the PV KO mouse, it was tempting to hypothesize
that mutations in PVALB, the gene coding for PV, could
be present in patients with GS heterozygous or in ones
negative for SLC12A3 mutations [32]. The PVALB gene,
localized on chromosome 22 (22q12-q13.1), has not been
linked to any human disorder so far. Direct sequencing of
PVALB was performed in 132 GS patients harbouring
only one (n = 53) or no (n = 79) mutant SLC12A3 allele.
The possible interference of biallelic SNPs (single nucleo-
tide polymorphisms) on normal transcription or normal
splicing was investigated. No sequence variants resulting
in amino acid substitution or a truncated protein within
the PVALB gene were found in the 264 chromosomes
tested. Ten biallelic SNPs, including six novel polymorph-
isms, were identiﬁed: ﬁve in the 5′ UTR, none of them
affecting predicted regulatory elements; three in the
coding region, without alteration of the consensus splice
sites and two in the 3′ UTR. The observed allelic frequen-
cies did not differ signiﬁcantly between GS patients and
controls. These results strongly suggest that mutations in
the PVALB gene are not involved in the classical form of
GS [32].
Despite these negative results, it may be of interest to
screen for PVALB mutations in patients harbouring neuro-
logical symptoms, such as epileptic seizures, in particular
when these manifestations are linked to hypomagnesae-
mia. Central manifestations have been described in Pvalb
KO mice, suggesting that a distinct neurological pheno-
type could result from the lack of PV (see below). One
could also hypothesize that changes in the expression or
function of PV (or in the Ca2+ signalling pathway in DCT
cells) may participate in the individual response to thia-
zide diuretics [12].
PVand renal cell carcinoma
In more than 90% of cases, renal cell carcinoma (RCC)
originates from tubular cells. The accurate typing of RCC
has important implications for prognosis and therapy. In a
normal clinical setting, the histologic diagnosis of RCC is
made by routine light microscopy of haematoxylin–eosin
stained sections. However, immunohistochemical analysis
based on segmental markers is important for the differen-
tial diagnosis of non-renal cell neoplasms mimicking
RCC, the differentiation of histological subtypes or rare
RCC, the analysis of a small biopsy specimen and most
importantly, the recognition of RCC metastases in distant
organs. The immunohistochemical diagnosis of RCC is
based on a set of markers indicative of the nephron
segment of origin. As mentioned before, PV is exclu-
sively expressed in the ﬁrst part of the DCT in human
kidney [12]. Reactivity for PV is therefore used, along
with cadherin, claudins and S100A, as a highly speciﬁc
and reliable marker of chromophobe RCC and benign on-
cocytoma, two neoplasms deriving from the distal
nephron (Figure 3). In contrast, PV is not expressed in
other renal neoplasms and especially in clear cell and pa-
pillary RCC.
Chromophobe carcinoma accounts for 5% of all RCC
and is considered to present a rather indolent behaviour
with localization restricted to the kidney and nuclear
Grade 2 at presentation. It is classically divided into a
typical variant and an eosinophilic variant, with a differ-
ential diagnosis including clear cell carcinoma, papillary
RCC and benign oncocytoma. PV staining is a reliable
marker of chromophobe carcinoma, superior to Hale’s
colloidal iron and antimitochondrial 113-1 antibodies
[33]. Immunostaining for other distal Ca2+-binding
Fig. 3. PV as a marker of chromophobe RCC. Immunohistochemical
analysis reveals a strong and ubiquitous expression of PV in a
chromophobe renal carcinoma (Inset, illustrating the intense staining in
chromophobe cancer cells), and staining of the early DCT of the normal
renal parenchyma. (Image courtesy of Dr S. Aydin.)
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proteins such as calbindin-D28k is most often negative and
much less speciﬁc than PV for oncocytoma and chromo-
phobre RCC. Staining for PV is of limited value to differ-
entiate the eosinophilic variant of chromophobe RCC
from oncocytoma, the most common benign renal neo-
plasm. The distinction is particularly challenging for
so-called hybrid tumours, revealing features of both onco-
cytoma and chromophobe RCC and reﬂecting probably
the common origin of these two tumours. Nevertheless, a
negative or a patchy staining for PV is strongly suggestive
towards the diagnosis of oncocytoma [34]. PV is also
strongly expressed in the (rare) metastases from chromo-
phobe RCC [33, 35].
Instead of being only a simple marker, could PV be a
causative agent in renal tumour development? It is of in-
terest that β-PV (oncomodulin) has been shown to activate
cyclic nucleotide phosphodiesterase and can thereby act
as a cellular trigger protein [36]. Oncomodulin is fre-
quently expressed in mammalian tumours, for instance in
Morris hepatoma [37]. However, PV and oncomodulin
differ by their Ca2+-binding sites. Oncomodulin has one
Ca2+-speciﬁc, non-canonical site (CD domain) and one
mixed (Ca2+/Mg2+)-binding site (EF domain). The CD
domain shows signiﬁcant Ca2+-dependent conformation
changes, suggestive of additional sensor function for on-
comodulin [2]. An active role of PV in tumour genesis
cannot be excluded, but would be likely based on altered
intracellular Ca2+ signalling. Until now, no interacting
partner indicative of a Ca2+ sensor function has been
identiﬁed.
PV outside the kidney
PV is highly expressed in a subgroup of inhibitory
GABAergic interneurons in various brain regions includ-
ing cortex, hippocampus, striatum and cerebellum (for
more details, see [7]) and in fast-twitch muscle ﬁbres
[14]. It has been postulated that the absence of PV in
GABAergic interneurons and in particular in chandelier
cells and basket cells is correlated with an increased sus-
ceptibility to epileptic seizures in Pvalb KO mice [10].
The modulation of [Ca2+]cyt kinetics in neurons lacking
PV leads to increased facilitation of GABAergic trans-
mission to postsynaptic pyramidal cells, thus resulting in
a shift in the pyramidal cell’s ﬁring properties which
could, under certain experimental conditions, lead to epi-
leptogenic insults. Indeed, the severity of pentylenetetra-
zole-induced generalized tonic–clonic seizures is
signiﬁcantly greater in Pvalb KO mice compared with
wild-type littermates [10]. PV KO mice also display a
mild impairment in motor coordination and motor learn-
ing [38]. There is evidence that PV plays a similar role in
the epileptogenic activity of the human neocortex based
on results of PV immunoreactivity in epileptic foci [39].
With respect to fast-contracting muscle activity, the
contraction–relaxation cycle is prolonged in Pvalb KO
muscle ﬁbres, with a signiﬁcantly greater force generated
during a single twitch [9]. These changes result from an
altered shape of Ca2+ transients in the absence of PV.
A possible role of PV as a signal transduction modulator
in human parathyroid gland cells by affecting [Ca2+]cyt is
also envisaged, potentially related to the control of PTH
secretion [8].
Conclusion and perspectives
PV is a classical member of the EF-hand protein super-
family that plays a role in regulatory processes operating
in very distinct cell types. PV has been described as a Ca2+
buffer and Ca2+ transporter/shuttle protein, but diverse
experimental observations hint towards an additional role
in magnesium handling. It is particularly puzzling that PV
is exclusively expressed in the early part of the DCT of
the human and mouse kidneys. A role of PV in the renal
handling of electrolytes was demonstrated in Pvalb KO
mice, which showed a mild salt-losing phenotype with
salt craving, relatively similar to GS. A link between the
Ca2+-buffering capacity of PV and the expression of the
thiazide-sensitive NCC could be established, with poten-
tial relevance for the regulation of sodium transport in the
distal nephron. On the basis of these studies, PVALB has
been proposed as a candidate gene in patients presenting
with GS and displaying none or only a single mutant
SLC12A3 allele. However, no link between mutations in
PVALB and GS could be established so far. Variants in
PVALB have been described, but their relevance to kidney
function or response to thiazide diuretics, for instance, has
not been investigated. Finally, PV is considered a reliable
marker of chromophobe carcinoma and oncocytoma, two
neoplasms deriving from the distal nephron. The putative
role of PV in tumour genesis has not yet been investi-
gated. The role of PV in tissues apart from the kidney is
best understood in neurons, where its absence affects
short-term modulation of synaptic transmission.
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